Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
REDWOOD CITY, Calif., Jan. 02, 2018 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at the 36th annual J.P. Morgan healthcare conference on Monday, January 8, 2017 at 2:00 p.m. PT being held in San Francisco.
The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar), CHS-0214 (etanercept biosimilar), and CHS-3351 (ranibizumab biosimilar) as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT:
Patrick O'Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
+1 (650) 649-3527
